e medical data are often filed for each patient in clinical studies in order to inform decision-making. Usually, medical data are generally skewed to the right, and skewed distributions can be the appropriate candidates in making inferences using Bayesian framework. Furthermore, the Bayesian estimators of skewed distribution can be used to tackle the problem of decision-making in medicine and health management under uncertainty. For medical diagnosis, physician can use the Bayesian estimators to quantify the effects of the evidence in increasing the probability that the patient has the particular disease considering the prior information. e present study focuses the development of Bayesian estimators for three-parameter Frechet distribution using noninformative prior and gamma prior under LINEX (linear exponential) and general entropy (GE) loss functions. Since the Bayesian estimators cannot be expressed in closed forms, approximate Bayesian estimates are discussed via Lindley's approximation. ese results are compared with their maximum likelihood counterpart using Monte Carlo simulations. Our results indicate that Bayesian estimators under general entropy loss function with noninformative prior (BGENP) provide the smallest mean square error for all sample sizes and different values of parameters. Furthermore, a data set about the survival times of a group of patients suffering from head and neck cancer is analyzed for illustration purposes.
Introduction
Frechet distribution (FD) was introduced by Maurice Frechet (1878-1973) for largest extremes [1] . It had been derived with nonnegative initial variates. e FD deals with extreme events and also recognized as extreme value Type-II distribution.
e cumulative distribution function of threeparameter FD is
where α is the shape, λ is the scale, and η is the location parameter. If η � 0 then it becomes two-parameter FD. e corresponding probability density function is f(x; α, λ, η) � α λ
the best linear invariant estimators of location and scale parameters of FD under progressive Type-II censoring, respectively. Abbas and Tang [9] discussed classical as well as the Bayesian estimators of FD assuming that the shape parameter was known. Abbas and Tang [10] developed maximum likelihood and least squares estimators for FD with Type-II censored samples. Furthermore, Abbas and Tang [11, 12] derived the reference and matching priors for the Frechet stressstrength model and developed Bayesian estimators for FD under reference prior, respectively. Nasir and Aslam [13] obtained Bayes estimators of FD and their risks by using four loss functions under Gumbel Type-II prior and Levy prior. Yet, the Bayesian analysis of three-parameter FD is not conducted. e aim of this paper is to develop Bayesian estimators for three-parameter FD using noninformative prior and gamma prior under two loss functions for the case of complete samples. Including this introduction section, the rest of the paper unfolds as follows: in Section 2, maximum likelihood estimators (MLEs) for the parameters are obtained. In Section 3, Bayesian estimators based on different loss functions by taking noninformative and gamma priors are derived. e proposed estimators are compared in terms of their mean squared error (MSE) in Section 4. Section 5 illustrates the applications of proposed estimators using head and neck cancer data set. Finally, conclusions and recommendations are presented in Section 6.
Maximum Likelihood Estimation
Let X 1 , X 2 , . . . , X n be random samples of size n from a threeparameter FD, then the likelihood function of (2) is
e corresponding log-likelihood function is Ł � log Ł x; α, λ, η � n log(α) + nα log(λ)
from equation (4), we have
Clearly, the above equations cannot be written in a closed form. erefore, BFGS quasi-Newton optimization method (Broyden Fletcher GoldFarb Shanno, Battiti, and Masulli [14] ) is applied to compute the MLEs.
Bayesian Estimation
In Bayesian estimation, we consider the two types of loss functions. e first is LINEX loss function, introduced by Varian [15] . is loss function was widely used by several authors, for example, Rojo [16] , Basu and Ebrahimi [17] , Pandey [18] , Soliman [19] , and Soliman et al. [20] . e second is general entropy loss function (GELF), defined by Calabria and Pulcini [21] . For Bayesian analysis, we need prior distribution. When prior information about the parameters is unavailable, then the noninformative prior can be considered for the Bayesian study. So, we supposed the noninformative form of priors for the all unknown parameters α, λ, and η of three-parameter FD as
If someone has a few information about parameters, then informative priors may be used for Bayesian analysis. It is noted that FD converts an inverse exponential distribution if its shape parameter equal to 1 and takes the form of the inverse Rayleigh distribution for shape parameter equal to 2, and when shape equal to 0.5, it approximates the inverse gamma distribution. So, we consider gamma prior for the scale parameter by assuming that shape parameter is known and independent priors for the shape and location parameters. us the proposed prior is
e joint prior distribution of parameters α, λ, and η is
e joint posterior density can be written as
Posterior distribution (9) takes a ratio form that cannot be reduced to a closed form. erefore, we use Lindley's approximation [22] to get the Bayesian estimate, which can be written as
e detail of equation (10) is given in Appendix. erefore, the approximate Bayesian estimators of parameters α, λ, and η by using noninformative prior under LINEX loss function are
Bayesian estimators of parameters α, λ, and η with gamma prior under LINEX loss function are
Similarly, Bayesian estimators of α, λ, and η using noninformative prior under GELF are
Bayesian estimators of parameters α, λ, and η with gamma prior under GELF are
where α, λ, and η are the ML estimates of parameters α, λ, and η, respectively. Further, the observed Fisher information matrix is obtained by taking the second and mixed partial derivatives of equation (4) with respect to parameters α, λ, and η, respectively, provided in Appendix.
Simulation Study
To demonstrate the performance of the proposed Bayesian estimators with their ML counterpart in terms of biases and MSE (within parenthesis), different sample sizes and different values of parameters are considered using Monte
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Carlo simulation. Monte Carlo simulation is conducted as follows:
(1) Take the initial values of α, λ, and η, respectively. Samples are generated from the FD using inverse transformation technique, i.e., X(
is the function of α, λ, and η using informative and noninformative priors and R is the number of iterations. (3) e process is replicated 3000 times for each sample size and averages of these estimates and the corresponding MSEs (within parenthesis) were calculated for each method.
e results are listed in Tables 1-4 for comparison purposes. Table 1 when the sample size increases. However, similar performance can be observed for large sample sizes. (iv) Based on simulation study and real data analysis, we suggest that the BGENP estimators in each scenario execute considerably, because the MSE is significantly smaller.
Data Analysis
For exemplification purposes, the data set presented in Table 5 reported by Efron [23] represents the survival times of a group of patients suffering from head and neck cancer and treated using a combination of radiotherapy and chemotherapy. e data set consists of 44 observations. Parametric analysis is performed to determine the bestfitted probability distribution function that characterizes the survival times of a group of patients suffering from head and neck cancer. e distribution in Figure 1 is highly skewed to the right. e distribution curve is asymmetric being stretched out to the right. Among the skewed distributions, FD is fitted to survival times of a group of patients suffering from head and neck cancer, parameters are estimated by using ML and Bayesian methods, and the results are presented in Table 6 for comparison purposes.
e Kolmogorov-Smirnov (KS) test along with P values is used to quantify the model.
Further, P values of KS test are significant at 5% level of significance except BLGP, which may indicate that the rest of the estimators are most appropriate for estimating the parameter of FD. Moreover, different estimates can also be visualized in Figure 1 , in which the x-axis represents the survival times of a group of patients suffering from head and neck cancer while the Frechet density function of survival is taken on the y-axis. .1562) 
Conclusion and Recommendations
Statistical decision theory addresses the state of uncertainty and provides a rational framework for dealing problems of medical decision-making.
e Bayesian paradigm represents the probabilistic relationships between diseases and symptoms. Although medical data are generally skewed to the right, positively skewed distributions are reasonably competitive when describing unimodal medical data. In this study, an attempt has been made to examine the Bayesian estimators for three-parameter FD with medical applications.
e Bayesian estimators are obtained using LINEX and GE loss functions considering gamma and noninformative priors through Lindley approximation. It is concluded that BGENP performed quite well in estimating the parameters of FD in terms of MSE as compared to other estimators. However, Bayesian and MLEs get closer in terms of MSEs for larger sample sizes.
ough computation of Lindley's method is based on the MLEs, it performs well for various sample sizes. e speed of convergence of Lindley's method is so fast for all problems and may rely on initial points. Based on these findings, it can be safely concluded that parametric FD is most suitable for describing the medical related data. e study will offer a framework for testing features of other skewed distributions considering Bayesian framework with medical data. us, providing a more detailed and accurate understanding of the distribution of medical data and professionals can make decisions on rational bases. Moreover, Survival times of patients suffering from head and neck cancer 
